Investor Relations

Press Releases

2020-12-03

Enlivex reports further success in Covid-19 trial

Seven severely ill patients treated with Enlivex's Allocetra, have fully recovered.
2020-11-05

Enlivex KOL Call on COVID-19

The Staging of a New Disease and Its Implications for Treatment Options
2020-10-01

5 patients leave Hadassah coronavirus-free after clinical trial

All five in serious or critical condition before being treated with Allocetra
2020-02-16

Israeli firm ready to assist coronavirus victims with novel drug

The innovative therapy is based on the research of Prof. Dror Mevorach

Paradigm shifting immunotherapy
For complex, life-threatening indications without therapies

Advanced clinical-stage pipeline
Promising results of PhIb (sepsis) and PhIIa (GvHD) studies, initiating Sepsis Phase IIb study

Multi-billion dollar
underserved markets
Sepsis | Solid Tumors, Covid-19,
Bone-Marrow Transplantations

Short regulatory approval pathway
Specialized regulation in Europe potentially enabling post-Phase II marketing approval

Strong leadership
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

Cash balance
~$60 Million invested; Cash balance supporting multiple clinical milestone within 18-24 months

Date	Form	Description	Download

Charter of the Audit Committee of the Board of Directors	download
Charter of the Compensation Committee of the Board of Directors	download
Code of Business Conduct and Ethics	download
Disclosure Policy	download
Employee Complaint Procedures for Accounting and Auditing Matters	download
Insider Trading Policy	download

14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072 | F +972.2.6708070
info@enlivex.com